197 related articles for article (PubMed ID: 22109892)
1. Increased numbers of nonattached osteoclasts after long-term zoledronic acid therapy in mice.
Kuroshima S; Go VA; Yamashita J
Endocrinology; 2012 Jan; 153(1):17-28. PubMed ID: 22109892
[TBL] [Abstract][Full Text] [Related]
2. Teriparatide and the treatment of bisphosphonate-related osteonecrosis of the jaw: a rat model.
Ersan N; van Ruijven LJ; Bronckers AL; Olgaç V; Ilgüy D; Everts V
Dentomaxillofac Radiol; 2014; 43(1):20130144. PubMed ID: 24170800
[TBL] [Abstract][Full Text] [Related]
3. Long-term therapy with intravenous zoledronate increases the number of nonattached osteoclasts.
Nagata MJH; Messora MR; Antoniali C; Fucini SE; de Campos N; Pola NM; Santinoni CS; Furlaneto FAC; Ervolino E
J Craniomaxillofac Surg; 2017 Nov; 45(11):1860-1867. PubMed ID: 28958784
[TBL] [Abstract][Full Text] [Related]
4. A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis.
Le Goff B; Soltner E; Charrier C; Maugars Y; Rédini F; Heymann D; Berthelot JM
Arthritis Res Ther; 2009; 11(6):R185. PubMed ID: 20003278
[TBL] [Abstract][Full Text] [Related]
5. OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.
de Molon RS; Shimamoto H; Bezouglaia O; Pirih FQ; Dry SM; Kostenuik P; Boyce RW; Dwyer D; Aghaloo TL; Tetradis S
J Bone Miner Res; 2015 Sep; 30(9):1627-40. PubMed ID: 25727550
[TBL] [Abstract][Full Text] [Related]
6. Mevalonates restore zoledronic acid-induced osteoclastogenesis inhibition.
Nagaoka Y; Kajiya H; Ozeki S; Ikebe T; Okabe K
J Dent Res; 2015 Apr; 94(4):594-601. PubMed ID: 25535203
[TBL] [Abstract][Full Text] [Related]
7. [Markers of bone metabolism in multiple myeloma patients switched from zoledronic acid to denosumab].
Tatekoshi A; Sato T; Ibata S; Hashimoto A; Kamihara Y; Horiguchi H; Ono K; Takada K; Iyama S; Takimoto R; Kobune M; Kato J
Rinsho Ketsueki; 2014 Nov; 55(11):2271-6. PubMed ID: 25501406
[TBL] [Abstract][Full Text] [Related]
8. Effect of anti-angiogenesis induced by chemotherapeutic monotherapy, chemotherapeutic/bisphosphonate combination therapy and anti-VEGFA mAb therapy on tooth extraction socket healing in mice.
Akita Y; Kuroshima S; Nakajima K; Hayano H; Kanai R; Sasaki M; Sawase T
J Bone Miner Metab; 2018 Sep; 36(5):547-559. PubMed ID: 29043461
[TBL] [Abstract][Full Text] [Related]
9. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties.
Pozzi S; Vallet S; Mukherjee S; Cirstea D; Vaghela N; Santo L; Rosen E; Ikeda H; Okawa Y; Kiziltepe T; Schoonmaker J; Xie W; Hideshima T; Weller E; Bouxsein ML; Munshi NC; Anderson KC; Raje N
Clin Cancer Res; 2009 Sep; 15(18):5829-39. PubMed ID: 19737962
[TBL] [Abstract][Full Text] [Related]
10. Cocultures of osteoblasts and osteoclasts are influenced by local application of zoledronic acid incorporated in a poly(D,L-lactide) implant coating.
Greiner S; Kadow-Romacker A; Schmidmaier G; Wildemann B
J Biomed Mater Res A; 2009 Oct; 91(1):288-95. PubMed ID: 18980195
[TBL] [Abstract][Full Text] [Related]
11. Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro.
Schindeler A; Little DG
Biochem Biophys Res Commun; 2005 Dec; 338(2):710-6. PubMed ID: 16243296
[TBL] [Abstract][Full Text] [Related]
12. Zoledronate promotes bone formation by blocking osteocyte-osteoblast communication during bone defect healing.
Cui P; Liu H; Sun J; Amizuka N; Sun Q; Li M
Histol Histopathol; 2018 Jan; 33(1):89-99. PubMed ID: 28345127
[TBL] [Abstract][Full Text] [Related]
13. Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice.
Kobayashi Y; Hiraga T; Ueda A; Wang L; Matsumoto-Nakano M; Hata K; Yatani H; Yoneda T
J Bone Miner Metab; 2010 Mar; 28(2):165-75. PubMed ID: 19882100
[TBL] [Abstract][Full Text] [Related]
14. Spontaneous osteonecrosis of the jaws in the maxilla of mice on antiresorptive treatment: a novel ONJ mouse model.
de Molon RS; Cheong S; Bezouglaia O; Dry SM; Pirih F; Cirelli JA; Aghaloo TL; Tetradis S
Bone; 2014 Nov; 68():11-9. PubMed ID: 25093262
[TBL] [Abstract][Full Text] [Related]
15. Bone-site-specific responses to zoledronic acid.
Vermeer J; Renders G; van Duin MA; Jansen I; Bakker LF; Kroon SA; de Vries TJ; Everts V
Oral Dis; 2017 Jan; 23(1):126-133. PubMed ID: 27706930
[TBL] [Abstract][Full Text] [Related]
16. Controlled delivery of zoledronate improved bone formation locally in vivo.
Gou W; Wang X; Peng J; Lu Q; Wang Y; Wang A; Guo Q; Gao X; Xu W; Lu S
PLoS One; 2014; 9(3):e91317. PubMed ID: 24618585
[TBL] [Abstract][Full Text] [Related]
17. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling.
McDonald MM; Dulai S; Godfrey C; Amanat N; Sztynda T; Little DG
Bone; 2008 Oct; 43(4):653-62. PubMed ID: 18582604
[TBL] [Abstract][Full Text] [Related]
18. Promotion of peri-implant bone healing by systemically administered parathyroid hormone (1-34) and zoledronic acid adsorbed onto the implant surface.
Li YF; Li XD; Bao CY; Chen QM; Zhang H; Hu J
Osteoporos Int; 2013 Mar; 24(3):1063-71. PubMed ID: 23296744
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapeutic and antiresorptive combination therapy suppressed lymphangiogenesis and induced osteonecrosis of the jaw-like lesions in mice.
Kuroshima S; Yamashita J
Bone; 2013 Sep; 56(1):101-9. PubMed ID: 23727433
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid reduces bone loss and tumor growth in an orthotopic xenograft model of osteolytic oral squamous cell carcinoma.
Martin CK; Werbeck JL; Thudi NK; Lanigan LG; Wolfe TD; Toribio RE; Rosol TJ
Cancer Res; 2010 Nov; 70(21):8607-16. PubMed ID: 20959474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
